Dragonfly, Phase 1 DF1001 TriNKET®

(2023.6.3)

About DF1001

DF1001 is an investigational first-in-class immune engaging drug candidate targeting HER2 that drives immune activation in solid tumors. DF1001 stimulates co-activating NK receptors, where NKG2D and CD16 co-stimulation yields distinctive and potent NK cell, γδ T cell, and CD8+ T cell activation. DF1001 is being evaluated in adult patients for the treatment of advanced solid HER2-positive tumors. DF1001 was discovered and developed using Dragonfly's TriNKET Platform. DF1001 has the potential to stimulate effective anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. DF1001 is the most advanced in a pipeline of TriNKETs that Dragonfly is developing to address high unmet needs for patients across a broad range of disease areas.

 

About Dragonfly

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing therapies that use its novel bispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly-owned clinical assets and multiple assets in the clinic with partners, Dragonfly has a deep pipeline of wholly-owned preclinical candidates developed using its proprietary platforms as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. 

 

https://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-the-presentation-of-phase-1-df1001-trinket-dose-escalation-results-at-asco-2023-annual-meeting-301842370.html

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meetin